Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Market Cap	11.64M 13.35M 10.78M 10.09M 18.92M 1.26B 19.04M 128M 49.56M 620M 50.1M 49.03M 2.15B	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	9.93M 11.39M 9.2M 8.61M 16.15M 1.07B 16.24M 109M 42.28M 529M 42.75M 41.83M 1.84B	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	30.7%	Yield 2024 *	-	Yield 2025	-

04-15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/09/25	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/09/25	Celyad Oncology announces research facility divestiture	RE
29/09/25	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/09/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/08/25	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/07/25	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/07/25	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/06/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/06/25	Celyad Oncology Announces Strategic Review	CI
02/04/25	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/02/25	Celyad: share price soars on encouraging data

28/02/22	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/01/22	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/08/21	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/03/21	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/12/20	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

05-20	Celyad Oncology : AGM Minutes - informal translation EN	PU
04-02	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/09/25	Celyad Oncology : Announces Research Facility Divestiture	PU
12/09/25	Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	AQ
11/09/25	Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	PU

05-20	Celyad Oncology : AGO Procès Verbal - version FR
04-17	Celyad Oncology : Rapport Annuel 2025 FR
04-17	Celyad Oncology : Statutory Annual Accounts 2025 FR
04-17	Celyad Oncology : Shareholder Proxy Legal Entities FR / EN
04-17	Celyad Oncology : Shareholder Proxy Natural Persons FR / EN

Celyad SA Stock Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad SA

Latest news : Celyad SA

Analysts' recommendations: Celyad SA

Press Releases: Celyad SA

News in other languages: Celyad SA

Quotes and Performance

Managers and Directors: Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Hilde Windels CHM	Chairman	61	23/06/2022
Serge Goblet BRD	Director/Board Member	-	01/01/2008

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	13.35M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	-2.16%	+0.73%	+60.26%	+97.20%	23.61B
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.23%

	2024	2025
Net sales	186K 213K 172K 161K 302K 20.13M 304K 2.04M 792K 9.91M 801K 784K 34.4M	21K 24.09K 19.45K 18.21K 34.15K 2.27M 34.35K 231K 89.42K 1.12M 90.41K 88.47K 3.88M
Net income	-5.82M -6.68M -5.39M -5.05M -9.47M -630M -9.53M -63.99M -24.8M -310M -25.07M -24.54M -1.08B	830K 952K 769K 720K 1.35M 89.82M 1.36M 9.12M 3.53M 44.21M 3.57M 3.5M 154M
Net Debt	-3.3M -3.78M -3.05M -2.86M -5.36M -357M -5.39M -36.2M -14.03M -176M -14.19M -13.88M -609M	-1.71M -1.96M -1.58M -1.48M -2.78M -185M -2.79M -18.77M -7.27M -90.98M -7.35M -7.2M -316M